We are live on ! Find out more
NVAX icon

Novavax

7.47 USD
-0.25
3.24%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
7.55
+0.08
1.07%
1 day
-3.24%
5 days
-10%
1 month
-34.65%
3 months
-11.28%
6 months
-19.42%
Year to date
4.77%
1 year
20.1%
5 years
-96.41%
10 years
-71.27%
 

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Employees: 749

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 45.7%
Neutral 32.6%
Negative 21.7%
Positive
MarketBeat
5 days ago
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Neutral
PRNewsWire
11 days ago
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London Healthcare Conference, London, United KingdomFireside chat on Tuesday, November 17, 2026, at 5:00 p.m.
Novavax to Participate in Jefferies London Healthcare Conference
Positive
Zacks Investment Research
12 days ago
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Negative
Zacks Investment Research
16 days ago
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline
Positive
MarketBeat
16 days ago
Novavax Q3 Earnings Call Highlights
Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone payment for the vaccine technology company.
Novavax Q3 Earnings Call Highlights
Neutral
Seeking Alpha
17 days ago
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
Negative
Zacks Investment Research
17 days ago
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Neutral
PRNewsWire
17 days ago
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and SG&A expense guidance by $5 million at mid-point  In October, Novavax earned a $125 million milestone upon Sanofi's launch of Phase 3 influenza-COVID-19 combination vaccine trial in Europe Sanofi confirms their intent to initiate a U.S. Phase 3 influenza-COVID-19 combination vaccine trial in 2027 to support U.S. approval Differentiated C. difficile vaccine program anticipated to advance into the clinic as early as 2027 Multiple Novavax and partner-led experiments with Matrix-M ® currently underway in a wide array of infectious disease targets and oncology models Company to host conference call today at 8:30 a.m.
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Negative
Zacks Investment Research
24 days ago
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Neutral
PRNewsWire
24 days ago
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
The global flu and COVID-19 markets have a current combined value that exceeds $10 billion, with significant burden of disease 1 The combination vaccine candidate evaluated in this trial pairs Sanofi's leading high-dose flu vaccine with Novavax's differentiated COVID-19 vaccine Significant potential value remains in Sanofi partnership via additional future opportunities for milestones and royalties GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's COVID-19 vaccine, Nuvaxovid™.
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Price charts implemented using Lightweight Charts™